Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : Says Study of GS-6207 Showed HIV Capsid Inhibition Can Lead Viral Load Declines

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/22/2019 | 11:37am EDT

By Stephen Nakrosis

Gilead Sciences, Inc. (GILD) said Monday data from a Phase 1b study of its GS-6207 demonstrated "the first proof of concept that HIV capsid inhibition can lead to significant declines in viral load in vivo."

Gilead said GS-6207 is "an investigational long-acting antiretroviral agent," which was recently given a breakthrough therapy designation by the U.S. Food and Drug Administration. GS-6207 is a "potential therapy for heavily treatment-experienced people living with multi-drug resistant HIV," the company said.

Gilead said GS-6207 acts to interrupt "the activity of HIV capsid, a protein that surrounds and protects the virus' genetic material and essential enzymes." The company said it can potentially keep the virus from becoming infectious and accessing uninfected cells.

Gilead said the treatment's safety and efficacy have yet to be established.

Data from the study was presented at the International AIDS Society Conference on HIV Science in Mexico City.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
08/22GSK's long acting HIV injection gets boost from study
RE
08/21GILEAD SCIENCES : Statement on Petitions to U.S. Patent and Trademark Office on ..
PU
08/19Who is next in big pharma's merger spree?
RE
08/16GILEAD SCIENCES : European Medicines Agency Validates Marketing Application for ..
AQ
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/15STEALTH BIOTHERAPEUTICS : Reports First Half 2019 Financial Results and Recent B..
AQ
08/15GILEAD SCIENCES : Québec Provides Access to Biktarvy® for the Treatment of HIV
AQ
08/13GILEAD SCIENCES : Report
CO
08/12GILEAD SCIENCES : China National Medical Products Administration Approves Biktar..
AQ
08/12GILEAD SCIENCES : China National Medical Products Administration Approves Biktar..
AQ
More news
Financials (USD)
Sales 2019 22 314 M
EBIT 2019 11 591 M
Net income 2019 4 273 M
Debt 2019 3 023 M
Yield 2019 3,92%
P/E ratio 2019 18,3x
P/E ratio 2020 11,2x
EV / Sales2019 3,78x
EV / Sales2020 3,64x
Capitalization 81 332 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,39  $
Last Close Price 64,22  $
Spread / Highest target 47,9%
Spread / Average Target 25,2%
Spread / Lowest Target -6,57%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES2.67%81 332
VERTEX PHARMACEUTICALS11.18%47 356
REGENERON PHARMACEUTICALS-21.01%32 282
GENMAB29.13%13 323
NEUROCRINE BIOSCIENCES, INC.36.17%8 905
BEIGENE LTD--.--%8 692